Browse the evidence

Therapeutic strategies that promote significant and sustained weight loss (~10% of total body weight) are among the most efficient for treating NASH and T2D.

Weight loss interventions should be prioritized in managing NASH and T2D.

Tirzepatide would avert 45,609 obesity cases per 100,000 individuals over a lifetime.

Tirzepatide is effective in reducing obesity cases, suggesting its potential use in clinical practice.

Semaglutide would avert 32,087 obesity cases per 100,000 individuals over a lifetime.

Semaglutide is effective in reducing obesity cases, suggesting its potential use in clinical practice.

Semaglutide reduced body weight more in women than in men, with a mean difference of -9.6% in women and -7.2% in men.

Practitioners should note that women may experience greater weight loss with semaglutide treatment.

Limiting saturated fatty acids intake to <10% of total caloric intake in obesity and <7% in hypercholesterolemia is recommended.

Practitioners should advise patients to limit saturated fat intake according to these guidelines.

Daily dietary fiber intake should reach a level of 25-40 g.

Encourage patients to increase their dietary fiber intake to meet these levels.

Vegetables and fruits should be consumed at a daily minimum level of 200g (or 4-5 portions) each.

Advise patients to include at least 200g of vegetables and fruits in their daily diet.

Using tirzepatide resulted in a weight loss of 17.8% compared with 12.4% for semaglutide.

Tirzepatide may be more effective for weight loss in patients with type 2 diabetes.

Dietary protein recommendations for older adults should be increased to mitigate age-related decline in skeletal muscle.

Practitioners should consider recommending higher protein intake for older adults to support muscle health.

Alternative protein sources may support muscle anabolism in active older adults.

Practitioners should explore alternative protein sources for their potential benefits in older adults.

Tirzepatide treatment significantly reduced the 10-year predicted risk of developing type 2 diabetes compared with placebo in participants with obesity or overweight.

Practitioners can consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

At week 72, mean absolute T2D predicted risk score reductions were significantly greater in tirzepatide groups (5 mg, 12.4%; 10 mg, 14.4%; 15 mg, 14.7%) versus placebo (0.7%).

The specific dose of tirzepatide can be tailored to achieve greater reductions in diabetes risk.

For participants with and without prediabetes, risk reductions were significantly greater in tirzepatide groups versus placebo.

Tirzepatide may be beneficial for a broader range of patients, including those with prediabetes.

Varying exercise selection can influence muscle hypertrophy and strength gains.

Fitness professionals should consider incorporating a variety of resistance exercises to enhance muscle growth and strength.

Systematic variation in exercise selection enhances regional hypertrophic adaptations and maximizes dynamic strength.

Implementing a structured variation in resistance exercises can lead to better muscle development and strength outcomes.

Excessive, random variation in exercise selection may compromise muscular gains.

Avoid excessive changes in exercise selection to maintain optimal muscle growth and strength.

INV-202 produced a significant mean weight loss of 3.5 kg (3.3% compared with placebo participants who gained a mean 0.6 kg [0.5%]).

INV-202 may be an effective treatment for weight loss in individuals with metabolic syndrome.

INV-202 exhibited significant reductions in waist circumference and BMI (P ≤ 0.03).

INV-202 may help reduce waist circumference and BMI in this population.

An active perioperative GLP-1 RA prescription in patients with diabetes was associated with a significantly reduced risk of 30-day readmission (RR: 0.883; P = 0.028).

Practitioners may consider GLP-1 RA prescriptions to reduce readmission rates in diabetic surgical patients.

Metabolic bariatric surgery (MBS) was associated with greater total weight loss (mean 28.3%) compared to GLP-1 receptor agonists (mean 10.3%) in patients with class II and III obesity.

MBS may be a more effective option for significant weight loss in patients with higher obesity classes.

A Mediterranean diet should serve as a basis that can be restructured into other kinds of diets for NAFLD patients.

Practitioners should consider using a Mediterranean diet as a flexible foundation for dietary recommendations for NAFLD patients.

Dietary composition is important for long-term health outcomes in NAFLD patients.

Practitioners should prioritize healthy dietary compositions to ensure long-term safety and efficacy for NAFLD patients.

The intervention group achieved significantly higher protein intake at 26–28 weeks and 36–38 weeks gestation.

Practitioners should focus on increasing protein intake in pregnant women through structured dietary interventions.

The percentage of weight loss as fat-free mass (%FFML) using GLP-1RA-based agents was between 20% and 40%.

Practitioners can expect that GLP-1RA treatments may lead to significant fat-free mass loss.